Reglan is not FDA-approved for morning sickness, yet the acid reflux drug, also known as metoclopramide, is being prescribed "off label" to treat nausea and vomiting in pregnant women.

It is also being prescribed off-label to increase milk production in nursing mothers.

Metoclopramide has been recommended to nursing mothers for over 20 years, yet Reglan's label states that Reglan can pass into breast milk and may harm the baby.

Metoclopramide has been linked to tardive dyskinesia, a disabling and often permanent condition characterized by involuntary and repetitive movements. Symptoms of tardive dyskinesia include involuntary/repetitive movements of the extremities, lip smacking, grimacing, rapid eye movements or blinking and impaired movement of the fingers. There is no known treatment for this disfiguring condition, which can last a lifetime, affecting victims physically, mentally, emotionally, socially and vocationally.

The FDA issued its toughest warning (the black box warning) against metoclopramide on February 26, 2009. The warning enhanced the prescription labeling by adding stronger language about the risk of tardive dyskinesia. According to the warning "the risk of developing tardive dyskinesia increases with duration of treatment and total cumulative dose."

Reglan injury lawyer, Roger D. Drake, added that "It also warns that treatment longer than 12 weeks significantly increases this risk. The black box warning, however, fails to mention that metoclopramide can cause this condition even with short term use, although the risk grows with long term use."

Three months after the black box warning was issued, an article printed in the New England Journal of Medicine claimed that metoclopramide was safe for use by pregnant women. Not once throughout the article, was the black box warning or the risk of tardive dyskinesia mentioned. Mr. Drake added that, "Women need to be aware of the potential risk Reglan poses to themselves and their children."

The FDA has only approved metoclopramide tablets for the treatment of gastroesophageal reflux disease (GERD), and for the treatment of diabetic gastroparesis. The injectable solution of metoclopramide has been approved for the treatment of nausea and vomiting associated with cancer chemotherapy and to prevent the nausea or vomiting that may occur after surgery. It is only approved to be used on a short term basis.

Anyone suffering tardive dyskinesia symptoms after taking Reglan should contact their doctor and also a Reglan injury lawyer to seek compensation for their injuries